SN
SNDX.US Syndax Pharmaceuticals Inc
- Market cap
- USD 827M
- P/E
- -
- P/B
- 84.75x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SNDX.US undervalued?
Graham numberThe Graham number of Syndax Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Syndax Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Syndax Pharmaceuticals Inc yet.
Syndax Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid le…
Full company profileSyndax Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Syndax Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.22M | 2.11M | 1.52M | 1.52M | 1.52M | 140M | 127M | 0.00 | 23.7M | 172M | 295M |
| Gross Profit | 1.22M | 2.11M | 1.52M | 1.52M | 1.52M | 140M | -454K | -12.0K | 22.9M | 165M | 268M |
| Operating Income | -43.8M | -62.0M | -75.9M | -57.5M | -71.4M | 26.2M | -152M | -230M | -340M | -273M | -155M |
| EBITDA | -43.7M | -61.9M | -75.8M | -57.4M | -71.3M | 26.3M | -152M | -209M | -314M | -252M | -139M |
| Net Income | -44.5M | -60.8M | -74.0M | -56.0M | -73.1M | 24.9M | -144M | -209M | -319M | -285M | -189M |
| EPS | -3.04 | -2.90 | -2.92 | -1.84 | -1.77 | 0.48 | -2.37 | -2.98 | -3.72 | -3.29 | -2.10 |
| Balance Sheet | |||||||||||
| Total Assets | 109M | 137M | 83.9M | 63.5M | 301M | 450M | 497M | 613M | 725M | 530M | 693M |
| Total Liabilities | 24.9M | 32.9M | 30.9M | 31.9M | 48.4M | 41.3M | 29.8M | 58.7M | 437M | 465M | 710M |
| Shareholders' Equity | 84.1M | 104M | 53.0M | 31.6M | 252M | 408M | 467M | 554M | 288M | 64.6M | -17.2M |
| Cash & Short-term Investments | 105M | 133M | 80.9M | 59.8M | 293M | 447M | 484M | 578M | 583M | 414M | 427M |
| Total Debt | - | - | - | 897K | 20.5M | 21.0M | 1.16M | 1.64M | 346M | 346M | 589M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -35.2M | -47.4M | -68.5M | -50.6M | -71.3M | 29.1M | -134M | -161M | -275M | -323M | -144M |
| Capital Expenditure | 261K | 84.0K | 187K | 129K | 129K | 129K | 225K | 0.00 | 0.00 | 187K | 53.3K |
| Free Cash Flow | -35.4M | -47.5M | -68.7M | -50.7M | -71.4M | 29.0M | -134M | -161M | -275M | -323M | -144M |
| Ratios | |||||||||||
| ROE | -52.9% | -58.3% | -139.4% | -177.1% | -29.0% | 6.1% | -30.8% | -37.8% | -110.6% | -441.6% | - |
| ROA | -40.8% | -44.3% | -88.1% | -88.1% | -24.3% | 5.5% | -28.9% | -34.2% | -44.0% | -53.9% | -27.2% |
| Net Profit Margin | -3,645.2% | -2,884.3% | -4,875.5% | -3,688.5% | -4,816.7% | 17.8% | -113.6% | - | -1,346.1% | -165.6% | -64.0% |
| Debt to Equity | - | - | - | 0.03x | 0.08x | 0.05x | 0.00x | 0.00x | 1.20x | 5.36x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Syndax Pharmaceuticals Inc dividends
Syndax Pharmaceuticals Inc has not paid dividends in the last 9 fiscal years.
Who owns Syndax Pharmaceuticals Inc
- Insiders 1.67%
- Institutions 98.33%
- Public & others 0.00%
- Shares outstanding 90.0M
- Free float 81.2M
Top funds holding SNDX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 2.85M | 3.17% | +0.56% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 2.73M | 3.04% | +2.69% | Oct 2026 |
| iShares Russell 2000 ETF | 2.23M | 2.48% | 0.00% | Oct 2026 |
| Hood River Small-Cap Growth Instl | 1.21M | 1.35% | 0.00% | Jun 2026 |
| Franklin Biotechnology Discv A(acc)USD | 1.08M | 1.20% | 0.00% | Sep 2026 |
| BNP Paribas US Small Cap ClassicC | 1.06M | 1.18% | -0.76% | Sep 2026 |
| Fidelity Small Cap Index | 973K | 1.08% | +0.16% | Aug 2026 |
| Franklin Small Cap Growth Adv | 928K | 1.03% | 0.00% | Sep 2026 |
| Belfius Equities Cure C Cap | 925K | 1.03% | 0.00% | Apr 2026 |
| BNP Paribas Health Cr Innovtr Cl Cap | 852K | 0.95% | +5.24% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 834K | 0.93% | -0.38% | Oct 2026 |
| HBM Healthcare Investments AG Ord | 828K | 0.92% | +15.32% | Sep 2026 |
| Loomis Sayles Small Cap Growth Instl | 753K | 0.84% | 0.00% | Sep 2026 |
| Vanguard Strategic Equity Inv | 677K | 0.75% | +84.28% | Sep 2026 |
| iShares Biotechnology ETF | 636K | 0.71% | -0.19% | Oct 2026 |
| Franklin Biotechnology Discovery A | 583K | 0.65% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 518K | 0.58% | +1.13% | Sep 2026 |
| Nuveen Quant Small Cap Equity R6 | 517K | 0.57% | +1.62% | Sep 2026 |
| Rhenman Healthcare Equity L/S RC2 SEK | 487K | 0.54% | 0.00% | Jan 2026 |
| Schwab US Small-Cap ETF™ | 474K | 0.53% | +0.24% | Oct 2026 |
Top institutions holding SNDX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 9.02M | 10.02% | +9.27% | Jun 2026 |
| Kynam Capital Management, LP | 8.05M | 8.94% | 0.00% | Jun 2026 |
| The Goldman Sachs Group Inc | 5.86M | 6.51% | +17.30% | Jun 2026 |
| State Street Corp | 5.66M | 6.29% | +27.73% | Jun 2026 |
| Bank of America Corp | 4.05M | 4.49% | -4.82% | Jun 2026 |
| Vanguard Capital Management, LLC | 3.93M | 4.36% | +2.76% | Jun 2026 |
| Deerfield Management Co | 3.78M | 4.20% | 0.00% | Jun 2026 |
| Eversept Partners, LP | 2.80M | 3.11% | -3.03% | Jun 2026 |
| Geode Capital Management, LLC | 2.58M | 2.87% | +19.80% | Jun 2026 |
| Hood River Capital Management LLC | 2.56M | 2.85% | +8.92% | Jun 2026 |
| Kingdon Capital Management LLC | 2.50M | 2.78% | 0.00% | Jun 2026 |
| Franklin Templeton Inc | 2.29M | 2.54% | +6.34% | Jun 2026 |
| Millennium Management LLC | 2.05M | 2.28% | +929.43% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 1.92M | 2.13% | +10.63% | Jun 2026 |
| UBS Group AG | 1.89M | 2.10% | +64.15% | Jun 2026 |
| Elmind Capital LP | 1.86M | 2.06% | 0.00% | Jun 2026 |
| BNP Paribas Investment Partners SA | 1.79M | 1.99% | +3.33% | Jun 2026 |
| Candriam Luxembourg S.C.A. | 1.70M | 1.88% | +83.29% | Jun 2026 |
| Soleus Capital Management, L.P. | 1.63M | 1.81% | -5.73% | Jun 2026 |
| Two Sigma Investments LLC | 1.58M | 1.75% | -0.09% | Jun 2026 |
Syndax Pharmaceuticals Inc company profile
- Company name
- Syndax Pharmaceuticals Inc
- Ticker
- SNDX.US
- Exchange
- USA Stocks
- Listed since
- Mar 3, 2016
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 298
- Fiscal year end
- December
- Address
- 730 Third Avenue, New York, NY, United States, 10017
- Phone
- 781 419 1400
- Website
- syndax.com
About Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
Syndax Pharmaceuticals Inc management
10- Mr. Michael A. Metzger M.B.A.CEO & Director · born 1971
- Mr. Keith Alan Goldan CPACFO, Treasurer & Principal Accounting Officer · born 1971
- Mr. Luke J. Albrecht J.D.General Counsel & Corporate Secretary · born 1979
- Mr. Steven ClosterChief Commercial Officer · born 1969
- Dr. Nicholas A.J. Botwood B.Sc., MBBSHead of Research & Development and Chief Medical Officer · born 1968
- Dr. Peter Ordentlich B.Sc., Ph.D.Co-Founder & Chief Scientific Officer · born 1969
- Dr. Richard A. Heyman Ph.D.Co-Founder · born 1957
- Dr. Michael Downes Ph.D.Co-Founder
- Sharon KlahreVice President of Investor Relations & Communications
- Ms. Averi PriceSenior VP of Legal & Chief Compliance Officer